- Home
- ACIU vs LGI Comparison
ACIU vs LGI Comparison
Compare ACIU & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- LGI
- Stock Information
- Founded
- ACIU 2003
- LGI 2004
- Country
- ACIU Switzerland
- LGI United States
- Employees
- ACIU N/A
- LGI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- LGI
- Sector
- ACIU Health Care
- LGI
- Exchange
- ACIU Nasdaq
- LGI Nasdaq
- Market Cap
- ACIU 213.3M
- LGI 217.2M
- IPO Year
- ACIU 2016
- LGI N/A
- Fundamental
- Price
- ACIU $2.97
- LGI $17.39
- Analyst Decision
- ACIU Strong Buy
- LGI
- Analyst Count
- ACIU 2
- LGI 0
- Target Price
- ACIU $10.00
- LGI N/A
- AVG Volume (30 Days)
- ACIU 266.4K
- LGI 41.1K
- Earning Date
- ACIU 11-04-2025
- LGI 01-01-0001
- Dividend Yield
- ACIU N/A
- LGI 7.10%
- EPS Growth
- ACIU N/A
- LGI N/A
- EPS
- ACIU N/A
- LGI N/A
- Revenue
- ACIU $5,482,957.00
- LGI N/A
- Revenue This Year
- ACIU N/A
- LGI N/A
- Revenue Next Year
- ACIU $1,022.98
- LGI N/A
- P/E Ratio
- ACIU N/A
- LGI N/A
- Revenue Growth
- ACIU N/A
- LGI N/A
- 52 Week Low
- ACIU $1.43
- LGI $12.66
- 52 Week High
- ACIU $4.00
- LGI $16.68
- Technical
- Relative Strength Index (RSI)
- ACIU 44.78
- LGI 54.25
- Support Level
- ACIU $2.70
- LGI $16.46
- Resistance Level
- ACIU $3.13
- LGI $17.51
- Average True Range (ATR)
- ACIU 0.21
- LGI 0.36
- MACD
- ACIU -0.05
- LGI 0.02
- Stochastic Oscillator
- ACIU 32.50
- LGI 77.50
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.